SMS Pharmaceuticals Ltd Intimates of Credit RatingSMS Pharmaceuticals Ltd Intimates of Credit Rating

Introduction

Leading pharmaceutical company received credit ratings from CARE Ratings Limited, reaffirming long-term facilities at CARE A Positive and upgrading short-term facilities to CARE A1.

Share price movement of SMS Pharmaceuticals

On December 4, 2025, SMS Pharmaceuticals Ltd opened at ₹326.95, up 2.11% from its previous close of ₹320.20. The stock reached a high of ₹329.00 (2.78%) and a low of ₹319.60 (-0.19%). By 12:30 PM, it traded at ₹321.00, a 0.25% increase, with a market cap of ₹3,006.23 crore.

SMS Pharmaceuticals Receives Updated Credit Rating

SMS Pharmaceuticals Limited received a credit rating update from CARE Ratings Limited on December 3, 2025. The ratings cover the company’s long-term and short-term bank facilities.

The long-term bank facilities of ₹350.87 crore were reaffirmed at CARE A with a Positive outlook. The short-term bank facilities of ₹52.83 crore were upgraded to CARE A1 from CARE A2+.

The rating reflects the company’s operational and financial performance for FY25 and H1FY26. CARE Ratings Limited may review, revise, or reaffirm ratings periodically based on new information or developments.

Stock performance of SMS Pharmaceuticals for Period of 1 week, 6 months, and 1 year

SMS Pharmaceuticals Ltd delivered a 0.14% return over the past week. The stock gained 30.6% over the past six months and rose 22.0% over the past year.

Shareholding pattern of SMS Pharmaceuticals

Particulars	Sep 2025	Jun 2025	Mar 2025
Promoter	68.10%	66.30%	66.30%
FII	0.20%	0.00%	0.10%
DII	2.90%	3.00%	2%
Public	28.90%	30.70%	31.20%

About SMS Pharmaceuticals

SMS Pharmaceuticals Ltd (NSE: SMSPHARMA) is a diversified pharmaceutical company engaged in manufacturing Active Pharmaceutical Ingredients (API) and intermediates, offering integrated solutions across the pharmaceutical value chain for domestic and international markets.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs